Literature DB >> 30502412

Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study.

Khalaf Kridin1, Michal Shani2, Yochai Schonmann2, Shani Fisher3, Guy Shalom4, Doron Comaneshter5, Erez Batat5, Arnon D Cohen6.   

Abstract

BACKGROUND: The coexistence of psoriasis and hidradenitis suppurativa (HS) has been described, but the association between these conditions is yet to be firmly established.
OBJECTIVES: To study the association between psoriasis and HS using a large-scale real-life computerized database.
METHODS: A cross-sectional study was conducted comparing the prevalence of HS among patients with psoriasis and among age-, sex- and ethnicity-matched control subjects.
RESULTS: A total of 68,836 patients with psoriasis and 68,836 controls were included in the study. The prevalence of HS was increased in patients with psoriasis as compared to the control group (0.3% vs. 0.2%, respectively; OR, 1.8; 95% CI, 1.5-2.3; P<0.001). In a multivariate analysis adjusting for smoking, obesity, and other comorbidities, psoriasis was still associated with HS (OR, 1.8; 95% CI, 1.4-2.2; P<0.001). Patients with coexistent psoriasis and HS were significantly younger (39.0±15.7 vs. 42.6±21.2 years; P=0.015) and had a higher prevalence of obesity (35.1% vs. 25.3%; P=0.001) and smoking (58.5% vs. 37.3%; P<0.001) as compared to patients with psoriasis alone. LIMITATIONS: Retrospective data collection.
CONCLUSIONS: A positive association was observed between HS and psoriasis. Further longitudinal observational studies are necessary to establish these findings in other study populations.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Year:  2018        PMID: 30502412     DOI: 10.1016/j.jaad.2018.11.036

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Hidradenitis Suppurativa is Associated with Non-alcoholic Fatty Liver Disease: A Cross-sectional Study.

Authors:  Iris González-Villanueva; Cristina DeGracia; Mariana Planells; Inés Poveda; Pedro Álvarez; Luca Schneller-Pavalescu; Isabel Betlloch; Gregor B E Jemec; Jose M Ramos; Jose C Pascual
Journal:  Acta Derm Venereol       Date:  2020-08-18       Impact factor: 3.875

2.  Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.

Authors:  Luca Fania; Martina Morelli; Claudia Scarponi; Laura Mercurio; Fernanda Scopelliti; Caterina Cattani; Giovanni Luca Scaglione; Tiziano Tonanzi; Maria Antonietta Pilla; Gianluca Pagnanelli; Cinzia Mazzanti; Giampiero Girolomoni; Andrea Cavani; Stefania Madonna; Cristina Albanesi
Journal:  J Pathol Clin Res       Date:  2019-10-29

3.  Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population.

Authors:  Natalia Kirsten; Nicole Zander; Matthias Augustin
Journal:  Arch Dermatol Res       Date:  2020-04-22       Impact factor: 3.017

4.  Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.

Authors:  Eleftheria Tampouratzi; Theodora Kanni; John Katsantonis; Theodora Douvali
Journal:  F1000Res       Date:  2019-11-26

5.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

6.  Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study.

Authors:  Ezgi Özkur; Yasemin Erdem; İlknur Kıvanç Altunay; Damla Demir; Nurcihan Çalışkan Dolu; Erdinç Serin; Aslı Aksu Çerman
Journal:  An Bras Dermatol       Date:  2020-09-11       Impact factor: 1.896

7.  MCPIP1/Regnase-1 Expression in Keratinocytes of Patients with Hidradenitis Suppurativa: Preliminary Results.

Authors:  Piotr K Krajewski; Weronika Szukała; Agata Lichawska-Cieślar; Łukasz Matusiak; Jolanta Jura; Jacek C Szepietowski
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.